indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
all-news

Scientists at INST, Mohali innovate unique drug delivery method to improve brain TB treatment

IMT News Desk

The drug delivery technology used was nose-to-brain (N2B) drug delivery, which utilises the olfactory and trigeminal nerve pathways in the nasal cavity to bypass the blood brain barrier

Researchers have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines. The innovative drug delivery method can effectively treat brain TB, a life-threatening condition with a high mortality rate.

Scientists at the Institute of Nano Science and Technology (INST), Mohali, an autonomous institute of the Department of Science and Technology (DST) used tiny particles made of a natural material called chitosan, to deliver TB medicines directly to the brain through the nose, bypassing the BBB.

The scientist's team led by Rahul Kumar Verma along with Krishna Jadhav, Agrim Jhilta, Raghuraj Singh, Eupa Ray, Vimal Kumar, Awadh Yadav and Amit Kumar Singh developed chitosan nano-aggregates, tiny clusters of nanoparticles made from chitosan, a biocompatible and biodegradable material. These tiny particles, known as nanoparticles, were then made into slightly larger clusters called nano-aggregates, designed for easy nasal delivery. They can hold TB drugs like isoniazid (INH) and rifampicin (RIF). 

The drug delivery technology used was nose-to-brain (N2B) drug delivery, which utilises the olfactory and trigeminal nerve pathways in the nasal cavity to bypass the BBB. By delivering the drug through the nasal route, the nano-aggregates can transport the drugs directly into the brain, significantly improving drug bioavailability at the injection site.

Besides, chitosan is known for its mucoadhesive properties and sticks to the nasal mucosa, which helps the nano-aggregates stay in place and prolongs the time they can release the drug, enhancing its therapeutic effectiveness.

It could be applied to treat other brain infections, neurodegenerative diseases (like Alzheimer’s and Parkinson’s), brain tumours, and epilepsy by enabling efficient drug delivery to the brain.

PIB

Recommended

Ethiopian delegation meets key representatives from DCGI and the Indian Pharmacopoeia Commission

Metropolis Healthcare data reveals 1 in 3 Indians show early signs of metabolic syndrome

Karnataka sees steady diabetes burden over a decade: Neuberg Diagnostics

National summit on Diabetic Retinopathy unveils new guidelines with support from Roche India

Glenmark registers consolidated revenue of Rs 60,469 Mn in Q2FY26

Delhi to host 18th edition of CPHI & PMEC India 2025 from Nov 25 to 27, 2025

Pathkind and WebEngage unite to deliver personalised, data-driven patient experiences

Akums reports consolidated revenue of Rs 1,018 crore in Q2 FY26

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions